News and reporting on cell-free DNA testing.
The Series A financing will go toward expanding access to its liquid biopsy-based test to more patients in Asia and North America, it said.
The company incurred a net loss of $5.2 million, or $.10 per share, slightly exceeding the $.09 per share loss that analysts had predicted on average.
The company said it intends to use net proceeds from the offering to support development and commercialization for its DetermaVu and Razor assays.
The San Diego-based company said that the number of commercial samples received during the quarter grew 66 percent year over year.
The company expects to launch Signatera for clinical use in colorectal cancer next year and has started to recruit a sales team for the assay.
